Prevalence, management and control of diabetes mellitus and associated risk factors in primary health care in Portugal;Prevalência, tratamento e controlo da diabetes mellitus e dos factores de risco associados nos cuidados de saúde primários em Portugal

Revista Portuguesa de Cardiologia

Volumn 29, Issue 4, 2010, Pages 509-537

  Cortez Dias, Nuno ^a,b   Martins, Susana ^a,b   Belo, Adriana ^c   Fiuza, Manuela ^a,b  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c Bioestatista do Centro Nacional de Colecção de Dados em Cardiologia da Sociedade   (Portugal)

Author keywords

Cholesterol; Coronary artery disease; Diabetes; Hypertension; Portugal; Primary care; Stroke; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT HUMAN INSULIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIABETES CONTROL; DIABETIC HYPERTENSION; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PORTUGAL; PREVALENCE; PRIMARY HEALTH CARE; QUESTIONNAIRE; STROKE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ADOLESCENT; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PRIMARY HEALTH CARE; RISK FACTORS; YOUNG ADULT;

EID: 77957348680     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Fiuza M, Cortez-Dias N, Martins S, Belo A. Metabolic Syndrome in Portugal: Prevalence and Implications in Cardiovascular Risk - Results from the VALSIM Study. Rev Port Cardiol 2008; 27(12):in press.
2. Do Carmo I, dos Santos O, Camolas J et al. Overweight and obesity in Portugal: national prevalence in 2003-2005. Obes Rev 2008; 9(1):11-19.
3. - Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141(6):421-431.
4. Gerstein HC, Pogue J, Mann JF et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005; 48(9):1749-1755. (Pubitemid 41317828)
5. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258):405-412. (Pubitemid 30609442)
6. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317(7160):703-713.
7. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351(9118):1755-1762. (Pubitemid 28269185)
8. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker- based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001; 24(12):2091-2096. (Pubitemid 33716527)
9. - Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351(19):1941-1951.
10. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311):1004-1010. (Pubitemid 34286537)
11. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25):3143-3421.
12. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5):1047-1053.
13. Falcão JM, Gouveia MF, Rosa AV, Sá JV, Valente MF. Epidemiologia da Diabetes: Parte I- Prevalência da doença e de alguns factores de risco numa coorte de diabéticos portugueses. Revista Portuguese de Clínica Geral 1996; 13:213-228.
14. Balkau B, Deanfield JE, Despres JP et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007; 116(17):1942-1951. (Pubitemid 350287090)
15. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003; 26(1):61-69.
16. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28(1):88-136.
17. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837-853.
18. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5):383-393. (Pubitemid 36159355)
19. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24):2545-2559. (Pubitemid 351831356)
20. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141(6):413-420.
21. Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 2008; 31(1):102-104.
22. De Macedo ME, Lima MJ, Silva AO, Alcantara P, Ramalhinho V, Carmona J. Prevalence, awareness, treatment and control of hypertension in Portugal. The PAP study. Rev Port Cardiol 2007; 26(1):21-39. (Pubitemid 46423622)
23. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11(3):309-317.
24. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59(1):8-13. (Pubitemid 9082394)
25. Mitchell BD, Stern MP, Haffner SM, Hazuda HP, Patterson JK. Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic whites. San Antonio Heart Study. Am J Epidemiol 1990; 131(3):423-433. (Pubitemid 20051738)
26. Krolewski AS, Warram JH, Cupples A, Gorman CK, Szabo AJ, Christlieb AR. Hypertension, orthostatic hypotension and the microvascular complications of diabetes. J Chronic Dis 1985; 38(4):319-326. (Pubitemid 15044150)
27. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356(9246):1955-1964.
28. Lip GY, Beevers DG. More evidence on blocking the renin-angiotensin- aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2). J Hum Hypertens 2003; 17(11):747-750. (Pubitemid 37441430)
29. Pablos-Velasco P, Gonzalez-Albarran O, Estopinan V, Khanbhai A. Blood pressure, antihypertensive treatment and factors associated with good blood pressure control in hypertensive diabetics: the Tarmidas study. J Hum Hypertens 2007; 21(8):664-672. (Pubitemid 47162729)
30. Garcia VO, Vicente LJ, Vegazo O, Jimenez Jimenez FJ, Llisterri Caro JL, Redon J. [Control of blood pressure in diabetic patients in primary care setting. DIAPA study]. Med Clin (Barc) 2003; 120(14):529-534.
31. Kemp TM, Barr EL, Zimmet PZ et al. Glucose, lipid, and blood pressure control in Australian adults with type 2 diabetes: the 1999-2000 AusDiab. Diabetes Care 2005; 28(6):1490-1492.
32. Mancia G, Volpe R, Boros S, Ilardi M, Giannattasio C. Cardiovascular risk profde and blood pressure control in Italian hypertensive patients under specialist care. J Hypertens 2004; 22(1):51-57. (Pubitemid 38293530)
33. Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316(7134):823-828. (Pubitemid 28112428)
34. Primatesta P, Poulter NR. Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxf) 2006; 64(3):292-298.
35. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 2000; 23(7):962-968. (Pubitemid 30480024)